These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 19939209)

  • 1. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 108():2-32. PubMed ID: 19939209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global burden of human papillomavirus and related diseases.
    Forman D; de Martel C; Lacey CJ; Soerjomataram I; Lortet-Tieulent J; Bruni L; Vignat J; Ferlay J; Bray F; Plummer M; Franceschi S
    Vaccine; 2012 Nov; 30 Suppl 5():F12-23. PubMed ID: 23199955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
    Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
    Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How much cervical cancer in Australia is vaccine preventable? A meta-analysis.
    Brotherton JM
    Vaccine; 2008 Jan; 26(2):250-6. PubMed ID: 18068276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions.
    Vinokurova S; Wentzensen N; Kraus I; Klaes R; Driesch C; Melsheimer P; Kisseljov F; Dürst M; Schneider A; von Knebel Doeberitz M
    Cancer Res; 2008 Jan; 68(1):307-13. PubMed ID: 18172324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of human papillomaviruses (HPV) in benign and malignant tumors of the upper respiratory tract.
    Shen J; Tate JE; Crum CP; Goodman ML
    Mod Pathol; 1996 Jan; 9(1):15-20. PubMed ID: 8821950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV type 18 is more oncopotent than HPV16 in uterine cervical carcinogenesis although HPV16 is the prevalent type in Chennai, India.
    Berlin Grace VM
    Indian J Cancer; 2009; 46(3):203-7. PubMed ID: 19574671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections.
    Wiley DJ; Masongsong EV; Lu S; Heather L S; Salem B; Giuliano AR; Ault KA; Haupt RM; Brown DR
    Cancer Epidemiol; 2012 Jun; 36(3):e183-9. PubMed ID: 22277329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
    Kohl I
    Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types.
    McKenzie ND; Kobetz EN; Hnatyszyn J; Twiggs LB; Lucci JA
    Gynecol Oncol; 2010 Mar; 116(3):572-7. PubMed ID: 19906410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of human papillomavirus types in anogenital warts of men.
    Chan PK; Luk AC; Luk TN; Lee KF; Cheung JL; Ho KM; Lo KK
    J Clin Virol; 2009 Feb; 44(2):111-4. PubMed ID: 19097933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract.
    Vinokurova S; Wentzensen N; Einenkel J; Klaes R; Ziegert C; Melsheimer P; Sartor H; Horn LC; Höckel M; von Knebel Doeberitz M
    J Natl Cancer Inst; 2005 Dec; 97(24):1816-21. PubMed ID: 16368943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the etiology of anal squamous carcinoma.
    Frisch M
    Dan Med Bull; 2002 Aug; 49(3):194-209. PubMed ID: 12238281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of mucosal human papillomavirus infection and associated diseases.
    Trottier H; Burchell AN
    Public Health Genomics; 2009; 12(5-6):291-307. PubMed ID: 19684442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.